The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Abdullaeva Sh.R.

Petrov National Cancer Research Center

Semiglazova T.Y.

N.N. Petrov National Medical Research Centre of Oncology;
I.I. Mechnikov North-West State Medical University

Artemyeva A.S.

N.N. Petrov National Medical Research Center for Oncology

Zagoruiko V.A.

N.N. Petrov National Medical Research Center of Oncology

Kudryashova T.I.

Petrov National Cancer Research Center

Filatova L.V.

Petrov National Cancer Research Center

Semiglazov V.V.

Petrov National Cancer Research Center;
Pavlov First St. Petersburg State Medical University

Krivorotko P.V.

Petrov National Cancer Research Center;
Mechnikov North-Western State Medical University

Semiglazov V.F.

Petrov National Cancer Research Center;
Mechnikov North-Western State Medical University

Tumor infiltrating lymphocytes (TILs) in triple negative breast cancer

Authors:

Abdullaeva Sh.R., Semiglazova T.Y., Artemyeva A.S., Zagoruiko V.A., Kudryashova T.I., Filatova L.V., Semiglazov V.V., Krivorotko P.V., Semiglazov V.F.

More about the authors

Read: 4260 times


To cite this article:

Abdullaeva ShR, Semiglazova TY, Artemyeva AS, et al. . Tumor infiltrating lymphocytes (TILs) in triple negative breast cancer. Russian Journal of Archive of Pathology. 2024;86(3):5‑11. (In Russ.)
https://doi.org/10.17116/patol2024860315

Recommended articles:
Trichomoniasis. Concentration of Pathogen DNA and Its Rela­tionship with Clinical Mani­festations of the Disease. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):656-661
M. geni­talium-infection. Correlation between pathogen’s DNA concentration and clinical picture of disease. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):446-452

References:

  1. Semiglazov V.F. Dependence of clinical course in breast cancer on tumour pathology. Radiobiol Radiother (Berl). 1974;15(3):361-364. 
  2. García-Martínez E, Gil GL, Benito AC, González-Billalabeitia E, Conesa MA, García García T, García-Garre E, Vicente V, Ayala de la Peña F. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16(6):488.  https://doi.org/10.1186/s13058-014-0488-5
  3. Issa-Nummer Y, Darb-Esfahani S, Loibl S, Kunz G, Nekljudova V, Schrader I, Sinn BV, Ulmer HU, Kronenwett R, Just M, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer — a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013;8(12):e79775. https://doi.org/10.1371/journal.pone.0079775
  4. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13(6):R126. https://doi.org/10.1186/bcr3072
  5. Gao ZH, Li CX, Liu M, Jiang JY. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer. 2020;20(1):1150. https://doi.org/10.1186/s12885-020-07654-y
  6. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al.; International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259-271.  https://doi.org/10.1093/annonc/mdu450
  7. Pruneri G, Vingiani A, Bagnardi V, Rotmensz N, De Rose A, Palazzo A, Colleoni AM, Goldhirsch A, Viale G. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. Ann Oncol. 2016;27(2):249-256.  https://doi.org/10.1093/annonc/mdv571
  8. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544-1550. https://doi.org/10.1093/annonc/mdu112
  9. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959-2966. https://doi.org/10.1200/JCO.2013.55.0491
  10. Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983-991.  https://doi.org/10.1200/JCO.2014.58.1967
  11. Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA, Allison KH. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867-3872. https://doi.org/10.1200/JCO.22.02864
  12. Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40-50.  https://doi.org/10.1016/S1470-2045(17)30904-X
  13. Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559-569.  https://doi.org/10.1200/JCO.18.01010
  14. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-113.  https://doi.org/10.1200/JCO.2009.23.7370
  15. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7): 860-867.  https://doi.org/10.1200/JCO.2011.41.0902
  16. Balic M, Thomssen C, Gnant M, Harbeck N. St. Gallen/Vienna 2023: optimization of treatment for patients with primary breast cancer — a brief summary of the consensus discussion. Breast Care (Basel). 2023;18(3):213-222.  https://doi.org/10.1159/000530584

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.